Skip to main content
. 2019 Mar 5;3(3):e193. doi: 10.1097/HS9.0000000000000193

Figure 1.

Figure 1

Clinical and molecular data. (A) Minimal residual disease monitoring in bone marrow using rearrangements of immunoglobulin light chain kappa and T-cell receptor gamma as leukemia-specific markers. (B) ZC3HAV1-ABL2 fusion sequence determined by reverse transcriptase-multiplex ligation probe amplification. The sequencing is performed by cyclic flowing of nucleotides (A, T, C, G). Each nucleotide incorporation gives a strong signal (peak indicated with A, T, C or G), which is proportional to the number of nucleotides incorporated. The sequence deduced is shown below with indication of the ZC3HAV1 part and ABL2 parts. (C) Domain organization of ABL2. (D) Domain organization of the putative ZC3HAV1-ABL2 fusion protein.